TY - JOUR
T1 - Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin
AU - Malaguarnera, Michele
AU - Motta, Massimo
AU - Vacante, Marco
AU - Malaguarnera, Giulia
AU - Caraci, Filippo
AU - Nunnari, Giuseppe
AU - Gagliano, Caterina
AU - Greco, Carmela
AU - Chisari, Giuseppe
AU - Drago, Filippo
AU - Bertino, Gaetano
PY - 2015
Y1 - 2015
N2 - Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting mainly from the complications of cirrhosis and HCC. The aim was to evaluate the impact on of supplementation with a new pharmaceutical complex of silybinvitamin E-phospholipids in patients with chronic hepatitis C treated with Pegylated-Interferon-α2b plus Ribavirin. In this prospective, randomized, placebo controlled, double blind clinical trial, 32 subjects with chronic hepatitis, received Pegylated-Interferon-α2b (1.5 mg/kg per week) plus Ribavirin and placebo, while 32 subjects received the same dosage of Pegylated-Interferon-α2b plus Ribavirin plus association of Silybin 47 mg + vitamin E 15 mg + phospholipids 97 mg in two pill for 12 months. Serum levels of the following markers of liver fibrosis were evaluated: transforming growth factor beta, hyaluronic acid, metalloproteinase 2, amino-terminal pro-peptide of type III procollagen, tissue inhibitor of matrix metalloproteinase type I. The comparison between group A and group B showed a significant difference in ALT (P
AB - Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting mainly from the complications of cirrhosis and HCC. The aim was to evaluate the impact on of supplementation with a new pharmaceutical complex of silybinvitamin E-phospholipids in patients with chronic hepatitis C treated with Pegylated-Interferon-α2b plus Ribavirin. In this prospective, randomized, placebo controlled, double blind clinical trial, 32 subjects with chronic hepatitis, received Pegylated-Interferon-α2b (1.5 mg/kg per week) plus Ribavirin and placebo, while 32 subjects received the same dosage of Pegylated-Interferon-α2b plus Ribavirin plus association of Silybin 47 mg + vitamin E 15 mg + phospholipids 97 mg in two pill for 12 months. Serum levels of the following markers of liver fibrosis were evaluated: transforming growth factor beta, hyaluronic acid, metalloproteinase 2, amino-terminal pro-peptide of type III procollagen, tissue inhibitor of matrix metalloproteinase type I. The comparison between group A and group B showed a significant difference in ALT (P
KW - Hepatitis C
KW - Interferons
KW - Liver fibrosis
KW - Ribavirin
KW - Silybin
UR - http://www.scopus.com/inward/record.url?scp=84950107034&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84950107034&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84950107034
VL - 7
SP - 2510
EP - 2518
JO - American Journal of Translational Research
JF - American Journal of Translational Research
SN - 1943-8141
IS - 11
ER -